BioPharmSignal logoBioPharmSignal

Biotech News

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

GRI Bio (GRI)GRI BioConference / presentation

Live video webcast on Wednesday, August 20 th at 2:20 PM ET

LA JOLLA, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=EA_rxh9L5oTDpBj2eT0AOf3o5vhevJZhhv2b1bLHeiaXl7_2EnOEfP9tulV2fo6oUe8M2n2omkxMblm7EXHSWg==" rel="nofollow"...

Related news

GRIGRI Bio2026-08-24 14:05 EST

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

GRIGRI Bio2026-06-18 13:31 EST

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

KNSAKiniksa2026-08-07 20:01 EST

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

KNSAKiniksa2026-05-29 20:01 EST

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

TLSATiziana Life Sciences2026-05-28 11:00 EST

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

XFORX4 Pharmaceuticals2026-05-27 11:00 EST

X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

XGNExagen2026-07-28 13:00 EST

Exagen Inc. to Participate in Upcoming Investor Conference

AVTXAvalo Therapeutics2026-07-22 11:00 EST

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

View all latest news

GRI Bio

BioRestorative or GRI is a historical small-cap biotech entry tied to biologics and regenerative or related platform work. Its story is best understood as an early-stage development attempt rather than a mature commercial franchise.

Recent company news

GRIGRI Bio2026-08-24 14:05 EST

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

GRIGRI Bio2026-06-18 13:31 EST

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

GRIGRI Bio2026-05-14 13:35 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

GRIGRI Bio2026-05-14 13:35 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

GRIGRI Bio2026-05-14 08:35 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

Stock data

Close
1.65 USD
Market cap
3.56M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States